Core Insights - Artiva Biotherapeutics has appointed Dr. Subhashis Banerjee as Chief Medical Officer, enhancing its development team focused on autoimmune diseases and cell therapy [1][2] - Dr. Banerjee has over 20 years of clinical development experience, previously holding significant roles at Bristol Myers Squibb and VYNE Therapeutics [1][2] - The company aims to advance its AlloNK® program for treating B-cell driven autoimmune diseases, leveraging Dr. Banerjee's expertise in regulatory approval of major therapies [2][5] Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company dedicated to developing safe and effective cell therapies for autoimmune diseases and cancers [5][6] - The lead program, AlloNK®, is a non-genetically modified NK cell therapy designed to enhance the efficacy of monoclonal antibodies for B-cell depletion [5] - Artiva was founded in 2019 as a spin-out from GC Cell, holding exclusive rights to NK cell manufacturing technology outside of Asia, Australia, and New Zealand [5] Recent Appointments - Dr. David Moriarty has been appointed as SVP of Clinical Operations, bringing nearly 25 years of experience in clinical research related to cell therapy and autoimmune diseases [3][4] - Benjamin Dewees has joined as SVP of Regulatory Affairs, with over 25 years of experience in regulatory affairs across various therapeutic areas [9] - Feng Xu has been appointed as SVP of Biometrics, contributing over 20 years of clinical development experience, including successful global regulatory filings [9]